Objective: To determine structural MRI and digital microscopic characteristics of REM sleep behavior disorder in individuals with low-, intermediate-, and high-likelihood dementia with Lewy bodies (DLB) at autopsy.
In several autopsy series, more than half of patients with Lewy-related pathology, including Lewy bodies and Lewy neurites, have concomitant Alzheimer pathology. 1-4 Thus, the third report of the dementia with Lewy bodies (DLB) Consortium criteria for neuropathologic diagnosis of DLB requires assessment of both presence and severity of Alzheimer-related pathology as well as density and distribution of Lewy-related pathology, with a final diagnosis expressed as a probability statement (low-, intermediate-, or high-likelihood) that the observed pathology would be associated with clinical features of DLB. 5 Both Alzheimer-and Lewy-related cerebral pathologies are characterized by early involvement of the limbic structures, 6, 7 specifically the entorhinal cortex, amygdala, and hippocampus. Preserved hippocampal volumes measured on antemortem MRI have been shown to be associated with high-likelihood DLB. 8, 9 Conversely, hippocampal atrophy was associated with lowand intermediate-likelihood DLB. Furthermore, patients with probable REM sleep behavior disorder (pRBD) had lower Braak neurofibrillary tangle (NFT) stage and lower neuritic plaque scores compared with those without RBD. 10 Because both structural MRI changes and RBD are associated with the pathologic classification of DLB, we sought to characterize the pathologic underpinnings of these associations.
Our objectives were 3-fold: first, to determine neuropathologic differences among patients with and without RBD in hippocampus and amygdala; second, to determine the structural MRI differences among patients with and without RBD; third, to determine the relationship between structural MRI abnormalities and pathologic hallmarks of Alzheimer-and Lewy-related pathologies-specifically, phospho-tau, b-amyloid, and a-synuclein burdens as assessed with state-of-the-art digital microscopic methods.
METHODS Subjects. The initial study cohort included participants who had been prospectively followed at the Rochester site of the Mayo Clinic Alzheimer's Disease Research Center (dementia clinic referral-based sample) or Alzheimer's Disease Patient Registry (community-based sample). Participants who had a 1.5-tesla research MRI and had come to autopsy between August 1998 and January 2012 were considered (n 5 636). Study subject's pathologic diagnosis had to include brainstem, transitional (limbic), or diffuse (neocortical) Lewy body disease, 7 which was later used with Braak NFT stage 6 to classify low-, intermediate-, and high-likelihood DLB according to the third report of the DLB Consortium (table 1). 5 Note that subjects with Lewy-related pathology limited to the amygdala were not included, as this type of pathology does not conform to neuropathologic classification of DLB likelihood. 11 Of the remaining subjects (n 5 157), further exclusions were made for significant neuropathology, such as neurodegenerative tauopathies, frontotemporal lobar degeneration, and hippocampal sclerosis. Patients were also excluded if they had concurrent illness at the time of MRI, or had structural abnormalities sufficient to interfere with cognitive function (e.g., cortical infarct, tumor, and subdural hematoma). Subjects were not excluded for leukoaraiosis or lacunar infarcts. Of the remaining 78 subjects who met inclusion/exclusion criteria, clinical history was then reviewed for a history of RBD-3 subjects lacked sufficient details to determine a positive or negative history. The final study cohort included 75 autopsied individuals (45 men and 30 women; age at death 56-99 years) who met all inclusion and exclusion criteria.
Standard protocol approvals, registrations, and patient consents. All patients or their informants/legal representatives signed consent to disclosure of clinical information, neuroimaging, and brain donation before time of death with appropriate ethical approval from the Mayo Clinic Institutional Review Board.
Neuropathologic measures. Standardized methods for sampling and neuropathologic examination were performed according to the CERAD (Consortium to Establish a Registry for Alzheimer's Disease) and the third report of the DLB Consortium. 5, 12 Braak NFT stage was determined based on the distribution of NFTs assessed with Bielschowsky silver stain. 6 Regional involvement of Lewy-related pathology was assessed with immunohistochemistry with a monoclonal a-synuclein antibody (appendix e-1 on the Neurology ® Web site at www.neurology.org). Table 1 shows the distribution of patients according to DLB neuropathologic classification.
Serial 5-mm-thick sections of amygdala and hippocampus were analyzed using Aperio digital microscopy hardware and software (Aperio Technologies, Vista, CA). Alzheimer-and Lewyrelated pathologies were immunostained and then analyzed using 3 custom-designed color deconvolution ImageScope algorithms. 13 Antibody information and detailed methods on quantification are available in appendix e-1. All neuropathologic analyses were performed blinded to group status.
Neuroimaging procedures. Antemortem MRIs were performed at 1.5 tesla (GE Healthcare, Waukesha, WI) using Table 1 Proportion of patients with neuropathologic findings associated with the likelihood of a DLB clinical syndrome 5
Lewy body-type pathology 7 Braak NFT stage 0-II Braak NFT stage III-IV Braak NFT stage 6 3-dimensional spoiled gradient recalled acquisition. For each subject, the T1 MRI scan was spatially normalized to a custom template and segmented in SPM5 as previously described. 14 RBD-positive and RBD-negative patients were compared with voxel-based morphometry (VBM) adjusting for age, sex, and time from MRI to death. 15 An in-house modified Automated Anatomic Labeling atlas was used for measuring hippocampus and amygdala volumes, as previously described. 14 The measured volume of amygdala and hippocampus ipsilateral to the pathologically assessed hemisphere in each individual was referenced to the total intracranial volume.
Clinical features and diagnoses. A consensus clinical diagnosis made at the time of the MRI was assigned by a panel of neurologists, neuropsychologists, and research nurses who reviewed the patient information. The diagnosis of dementia was made based on DSM-III-R. 16 The clinical diagnosis was made according to established criteria for DLB, 5 but because RBD was assessed in this study, only the core features were considered and RBD was not considered as a supporting feature for the clinical diagnosis of DLB. Diagnostic criteria for Parkinson disease, 17 Alzheimer disease (AD), 18 and mild cognitive impairment (MCI) were also used. 19 A Mayo Fluctuations Scale score $3 out of 4 was used to determine the presence/absence of fluctuations. 19 Information regarding the presence or absence of fully formed visual hallucinations was obtained from the informant. The presence of parkinsonism was determined by neurologic examination and required 2 of the 4 cardinal features: tremor, bradykinesia, rigidity, and postural instability.
Thirty-five patients were considered to have a positive history of RBD based on informant report from the Mayo Sleep Questionnaire, a highly sensitive (98%) and specific (74%) assessment of RBD, as previously described. 20 Overnight polysomnography was performed in 22 (63%) of these patients with a history of RBD with dream enactment behavior, and REM sleep without atonia was confirmed in all of them using established criteria by board-certified sleep specialists. 21 Polysomnography was not routinely performed on those without a history of RBD. In this report, patients with polysomnography-confirmed or clinically pRBD are referred to as pRBD-positive, and those without a history of RBD are referred to as pRBD-negative.
Statistical analyses. The median and interquartile ranges are reported-along with the unadjusted p values from a 2-sided, 2-sample Wilcoxon rank sum test for the continuous variables. For categorical variables, the number of subjects is reported as well as the percent and p values from a x 2 test. Pearson correlations are reported between imaging and pathology variables, adjusted for age, sex, and time from MRI scan to death. Results of multiple regression models across the entire cohort test the association between imaging and pathologic variables, again adjusted for age, sex, and time from MRI scan to death.
RESULTS Characteristics of patients. Patients were classified according to pathologic criteria from the third report of the Consortium for DLB as lowlikelihood (n 5 15; 20%), intermediate-likelihood (n 5 31; 41%), or high-likelihood (n 5 29; 39%) DLB (table 1) . The demographic, clinical, and pathologic information of pRBD-negative and -positive patients are summarized in table 2. Of the 75 patients studied, 47% were pRBD-positive. Those classified as pRBD-positive were younger and were more likely to be male. Given the age and sex differences between the pRBD groups, as well as differences in the MRIto-death interval, all further analyses were adjusted for these 3 covariates. Table 2 shows that 85% of pRBDnegative patients carried an antemortem clinical diagnosis of AD or MCI, and 80% had a low-likelihood or at most intermediate-likelihood of the clinical DLB syndrome based on neuropathology. In contrast, 89% of pRBD-positive patients carried antemortem clinical diagnoses of DLB or MCI, and 94% had intermediate-or high-likelihood DLB neuropathology. A greater proportion of pRBD-positive patients had diffuse cortical Lewy-related pathology (83%) compared with pRBD-negative patients (52%). A lower proportion of pRBD-positive patients had a neuropathologic diagnosis of AD (34%) compared with pRBD-negative patients (70%). Fluctuations, parkinsonism, and visual hallucinations were more frequent in pRBD-positive patients (table 2). Braak NFT stage was higher in pRBD-negative patients and indicative of NFT pathology in limbic regions as well as association cortices, whereas pRBD-positive patients had lower Braak NFT stage indicative of NFT pathology more restricted to limbic regions.
Pathologic findings in the hippocampus and amygdala.
Figure e-1 shows an example of the phospho-tau, b-amyloid, and a-synuclein immunohistochemistry and their respective analyzed markup images from a hippocampal section of a pRBD-negative patient. In the hippocampus ( figure 1A) , median phospho-tau was higher in the pRBD-negative group than in the pRBD-positive group (29.6% vs 14.5%, p 5 0.007). Similarly, b-amyloid burden was greater in the pRBDnegative compared with pRBD-positive group (1.2% vs 0.5%, p , 0.001). Hippocampal a-synuclein burden did not differentiate pRBD groups (0.9% vs 1.2%, p 5 0.25). In the amygdala (figure 1B), median phospho-tau was higher in the pRBD-negative group than in the pRBD-positive group (31.3% vs 10.9%, p , 0.001), and a similar relationship, to a lesser degree, was seen with b-amyloid burden (1.2% vs 0.6%, p , 0.001). a-Synuclein burden in the amygdala did not differentiate between those with and without pRBD (4.0% vs 2.8%, p 5 0.21).
MRI findings and pathologic correlation. Group comparisons of structural MRI were performed using VBM analysis in patients negative and positive for pRBD using a threshold of p , 0.001 adjusting for age, sex, and time from MRI to death and correction at a cluster level of 200 voxels (figure 2). Results show greater atrophy in pRBD-negative than pRBD-positive patients in the posterior cingulate, precuneus, lateral temporoparietal, hippocampus, and amygdala. The findings disappeared when we used a threshold of 0.05 correcting for multiple comparisons using false discovery rate. We did not find greater atrophy in patients who were positive compared with negative for pRBD on VBM analysis (p , 0.001; uncorrected for multiple comparisons).
The association of MRI volumes with underlying Alzheimer-and Lewy-related pathologies was assessed in the hippocampus and amygdala by combining the cases for Pearson correlation tests in the entire group, after adjusting for age at the time of MRI, sex, and the scan-to-death interval for each correlation (table 3) . There is an inverse relationship between the antemortem amygdala volume and phospho-tau burden, but not b-amyloid burden (table 3) . The association between volumes of the amygdala with a-synuclein burden did not reach statistical significance (p 5 0.056). Antemortem hippocampal volumes were inversely correlated with phospho-tau and b-amyloid, but not a-synuclein burdens (table 3) . Because both phosphotau and b-amyloid burdens correlated with hippocampal volume, we performed multiple regression modeling to determine the extent of this relationship, adjusting for age, sex, and scan-to-death interval. When both phospho-tau and b-amyloid burden were included in the same model, phospho-tau burden (p 5 0.05) was negatively associated (regression coefficient 26 3 10 24 , 95% confidence interval 21 3 10 23 , 21 3 10 25 ) with hippocampal volumes, but b-amyloid burden was not (p 5 0.11). The regression model with both phosphotau and b-amyloid burdens, adjusting for age at the time of the MRI, sex, and scan-to-death interval, explained 25% of the variance in hippocampal volume. DISCUSSION We report on a subset of patients with Lewy body pathology who met pathologic criteria for low-, intermediate-, and high-likelihood DLB and who underwent detailed MRI scans during life. Consistent with the literature, pRBD-positive patients were more often male and had a younger age at death. 22, 23 Not surprisingly, despite the presence of Lewy body pathology, the majority of patients in the low-likelihood DLB group met criteria for a clinical diagnosis of dementia with AD, whereas those in the intermediate-and high-likelihood DLB group were mixed in whether they met clinical criteria for probable DLB according to core features. pRBD was represented in both intermediate-and high-likelihood DLB, but was not present in all patients in those classification stages. As such, this comparison of pRBD-negative and pRBD-positive individuals is more than just a comparison between DLB and AD, although these pathologies are intermixed and one goal of this study was to examine whether relationships are evident among Lewy body and AD pathologies, MRI characteristics, and pRBD. Patients who were pRBD-positive had less Alzheimer-related pathology, greater frequency of diffuse (neocortical) Lewy body disease, and lower degree of atrophy on MRI compared with those who were pRBD-negative. Neuroimaging is recognized as a useful biomarker for the clinical diagnosis of DLB, and several neuroimaging findings have been included as suggestive and supportive features (e.g., preservation of medial temporal lobe on CT/MRI). 5, 9, 24 Consistent MRI findings in DLB point to relative preservation of medial temporal lobe structures, especially compared with AD. 8, 9, 25, 26 Given the increased odds of autopsyproven DLB when pRBD is considered, 1 we retrospectively demonstrated that neuroimaging differences existed in an autopsy cohort with a range of Alzheimer-and Lewy-related pathologies. Previous antemortem studies investigating neuroimaging differences in incidental RBD have reported inconsistent results, describing increased hippocampal gray matter density 27 and decreased parahippocampal gray matter volume compared with controls. 28 Although neuronal reorganization is speculated to underlie an increase in gray matter density, 27 our results support the concept of hippocampal preservation due to a lack of Alzheimerrelated neuropathology. Specifically, we show that atrophy in the hippocampus and amygdala on antemortem MRI in this autopsy cohort with a range of Alzheimer-and Lewy-related pathology was associated with phospho-tau burden. Moreover, regional cortical volumes on VBM further demonstrate preservation of temporoparietal cortical volume in DLB that is typically atrophic in AD. 9 While the investigations into the pathologic basis of medial temporal atrophy are limited, 29 investigations into neuroimaging differences in autopsied patients with a spectrum of Lewy-and Alzheimer-related neuropathology dichotomized by their clinical history of pRBD are even less common. Both Alzheimer-related and Lewy body-related pathologies are considered in the neuropathologic diagnosis of DLB, 5 and this study evaluates imaging techniques as a marker of this underlying pathology. Regardless of Lewy body-related pathology, the Braak NFT stage correlated with the extent of antemortem hippocampal atrophy, and the pRBD-negative group demonstrated an atrophy pattern mirroring what has been described as an "AD signature" in autopsyconfirmed AD. 30 Similarly, the posterior cingulate, precuneus, lateral temporoparietal cortex, hippocampus, and amygdala displayed greater atrophy in the pRBD-negative patients, a group that despite brainstem or limbic Lewy body pathology appears most dominated by Alzheimer-related pathology. This supports observations of high phospho-tau and b-amyloid burden in pRBD-negative patients, and highlights the need for assessment of both Alzheimer-and Lewyrelated pathologies when predicting the DLB clinical syndrome from pathologic data. 2, 5 Evaluation of neuroimaging associations with intermediate-likelihood DLB patients are of interest; however, hemispheric atrophy on structural MRI is at a disadvantage in distinguishing Lewy body-related pathologies. Other imaging markers, such as striatal dopamine transporter binding on PET or SPECT should be considered in follow-up studies seeking to discriminate low-, intermediate-, and high-likelihood DLB patients in retrospective autopsy cohorts. Our quantification methods included the area of burden occupied by the inclusions (i.e., NFT, senile plaques, and Lewy bodies), as well as the area occupied by neuritic pathology (i.e., neuropil threads and Lewy neurites). This distinguishes our methods from a previous study that excluded neuritic pathology on phospho-tau and a-synuclein immunohistochemistry in the qualitative assessment of medial temporal lobe atrophy in AD, DLB, and vascular cognitive impairment. 25 That study reported higher Braak NFT stage, area of NFT, and area of senile plaques correlated with greater medial temporal lobe atrophy across the entire sample. A regression analysis of Braak NFT stage, NFTs, senile plaques, and Lewy bodies found that only Braak NFT stage significantly predicted medial temporal lobe atrophy across the entire sample. These findings point to the significant effects of NFT pathology on medial temporal lobe structures; however, inclusion of Braak NFT stage in the model could have biased the results given the high level of correlation between NFT severity in the hippocampus and Braak NFT stage. 31 Regardless, the difference between this previous report and the current findings may point to the importance of considering both inclusions and neuritic pathology as the neuropathologic substrate underlying volume loss in hippocampus and amygdala. In a follow-up study utilizing quantitative neuroimaging methods to measure volumes of amygdala and hippocampus, the same methods for NFT area and plaque area were used, but both neuritic and Lewy body pathologies were quantified. 29 This study found that the greater burden of Lewy-related pathology, but not phospho-tau or b-amyloid, significantly correlated with smaller volumes of amygdala. We found a trend for association between volume of amygdala and a-synuclein burden, supporting that a-synuclein burden may modify integrity of the amygdala; however, a much stronger and significant association 32 was found between volume of amygdala and phospho-tau burden. Interestingly, hippocampal volume was not associated with a-synuclein burden in the current cohort. To determine the relative importance of b-amyloid and phospho-tau burdens for hippocampal volume, a multivariable regression model was used, which demonstrated that phospho-tau accumulation and not b-amyloid contributes to hippocampal volume loss. 31 A limitation of this study is the time from MRI to death, averaging 4.0 years for the entire cohort. This was addressed by controlling for MRI-to-death interval as a covariate in regression models. Another limitation is the use of a lenient threshold for VBM analyses that was not corrected for multiple comparisons. An additional limitation is reliance on clinical judgment or bed-partner descriptions in patients in whom a polysomnography was not performed. Ideally, pRBD status would be confirmed in all patients (and controls) using overnight polysomnography. Unfortunately, sleep studies are costly and rarely performed in controls without abnormal sleep indications. Lastly, referral bias could be a factor for any clinical setting and the current findings need to be replicated in epidemiology samples.
The importance of Alzheimer-related pathology in DLB cannot go unappreciated, especially when imaging markers are being used for patient selection in clinical trials, and likely will be used for treatment decisions in the future. 33 Patients with DLB who lack Alzheimer-like atrophy patterns on MRI and who have low cortical amyloid load on PET are more likely to cognitively respond to acetylcholinesterase inhibitor treatment compared with those with hippocampal atrophy and high cortical amyloid load on PET. 33 Thus, pRBD status and medial temporal lobe atrophy on MRI may have implications for identifying patients who may benefit from treatments targeting disease-specific proteins and associated clinical syndromes.
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